ClinicalTrials.gg
WithdrawnNCT03905109Updated Jul 31, 2024

Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients

A Phase 2/3 interventional study of ABX464 and Placebo in Crohn Disease, sponsored by Abivax S.A.. Withdrawn at 1 site in Belgium. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-31.

Sponsored by Abivax S.A. · Phase 2/3, Interventional, and Treatment

Why this study was withdrawn
Study design revised and to be found under new NCT06456593 ABX464-202

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 194 studies in Crohn Disease with a site in Belgium — 41 open to participants now, 56 under way, 29 of them phase 3. Crohn Disease · Belgium.

Enrollment
174th of 175
0 · median 211
Started
2022
with 7 others
Phase 2/3
5 of 194
1 open now
Registered
124th of 194
by date

Among the 194 studies in Crohn Disease with a site in Belgium, this one is the 174th largest by enrollment of the 175 interventional ones that give a count, is one of 8 that started in 2022, is one of 5 in phase 2/3, and was the 124th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

41 of the 194 studies in Crohn Disease with a site in Belgium are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Crohn Disease with a site in Belgium, or all of them as a file.
02

Study summary

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464, administered once daily (QD), in inducing clinical remission and endoscopic response in patients with moderate to severe active Crohn's disease (CD) who have inadequate response, loss of response, or intolerance to prior corticosteroid and/or immunosuppressant treatment and/or biologics. This study consists of a 28 day Screening Period, a 52 week Treatment Period; including a 12 week double blinded (Cohort 1) or open label (Cohort 2) Induction Phase and a 40 week double blinded (responders) or open label (nonresponders) Maintenance Phase; and a 4 week Follow up Period, which will consist of an End of Study (EOS) visit

Read the detailed description

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464, administered once daily (QD), in inducing clinical remission and endoscopic response in patients with moderate to severe active Crohn's disease (CD) who have inadequate response, loss of response, or intolerance to prior corticosteroid and/or immunosuppressant treatment and/or biologics. This study consists of a 28 day Screening Period, a 52 week Treatment Period; including a 12 week double blinded (Cohort 1) or open label (Cohort 2) Induction Phase and a 40 week double blinded (responders) or open label (nonresponders) Maintenance Phase; and a 4 week Follow up Period, which will consist of an End of Study (EOS) visit

Patient eligibility will be determined during a 4 week (28 days) Screening Period. Entry criteria will be based on confirmation of active moderate to severe ileal, ileocolic, or colonic CD. Approximately 930 patients will participate in this study (ABX464 Dose A N = 380, ABX464 Dose B N = 380, placebo N = 170).

On Day 0, eligible patients will be randomized into 2 cohorts:

  • Cohort 1: Double blinded Induction Phase according to a 1:1:1 ratio into 3 treatment groups as follows:

    • ABX464 - Dose A QD: 170 patients
    • ABX464 - Dose B QD: 170 patients
    • Matching Placebo: 170 patients
  • Cohort 2: Open-label Induction Phase according to a 1:1 ratio into 2 treatment groups as follows:

    • ABX464 - Dose A QD: 210 patients

At the end of the 12-week Induction Phase, all patients will be evaluated for the co-primary endpoints, namely induction of clinical remission and endoscopic improvement in addition to the secondary and exploratory endpoints. All patients will also be evaluated for treatment response. The determination of whether patients will be considered treatment responders versus nonresponders, responders being defined as patients with a reduction from baseline in Crohn's Disease Activity Index (CDAI) of ≥ 70 points.

Patients will be allocated to the different maintenance treatment regimens according to the following rules:

  • Patients who received ABX464 in the Induction Phase (coming from Cohort 1 and 2) and who were responders at Week 12 will be randomized 1:1:1 to receive either ABX464 Dose A QD, ABX464 Dose B QD, or placebo in a double-blinded manner, for an additional 40 weeks. Stratification factors used for re-randomization in the Maintenance Phase are previous failure to biologics and current corticosteroid treatment use.
  • Patients who received ABX464 or placebo in the Induction Phase (coming from Cohort 1 and 2) but who were not responders at Week 12 will be allocated to open label ABX464 Dose A QD. They will be evaluated 12 weeks later, and they will continue only if they have achieved clinical response at that timepoint.
  • Patients who received placebo (coming from Cohort 1) in the Induction Phase and who were responders at Week 12 will be allocated to receive placebo as part of their double blinded maintenance treatment.

At Week 24, nonresponders who received open label ABX464 Dose A QD in the Maintenance Phase will be assessed for treatment response. If patients have not achieved treatment response at Week 24, patients should discontinue study drug. All patients, including those who have had treatment response in Week 12, can be discontinued due to disease worsening.

Patients will also be evaluated for safety and efficacy throughout the Induction and Maintenance Phases. From Day 0 onwards, all eligible patients will be followed at the investigational site on Week 1, Week 2, Week 4, Week 8, Week 12, and every 4 weeks until Week 52. Ileocolonoscopy will be performed in accordance with the Schedule of Activities.

03

Conditions studied

  • Crohn Disease

Browse trials for

Keywords

  • Inflammatory Bowel Disorders
  • ABX464
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women age 18-75 years;
  • Patients must have a documented diagnosis (endoscopic with histology) of CD for ≥ 3 months before screening;
  • Patients must have active moderate to severe ileal, ileocolic, or colonic CD at baseline as defined by 220 ≤ CDAI > 450,
  • Patients must have a SES-CD score > 6 (≥4 if isolated ileal disease) at screening, assessed by ileocolonoscopy and confirmed by a central reading.
  • Patients must be willing and able to undergo endoscopy during screening after all other inclusion criteria have been met and at the end of Week 16.
  • Patients must have had either a documented inadequate response, no response, a loss of response, or an intolerance (defined as the occurrence of at least one Adverse Reaction leading to treatment discontinuation) to either amino-salicylates, treatment (i.e., azathioprine, 6-mercaptopurine, methotrexate, biologics (i.e. tumor necrosis factor inhibitors, vedolizumab, ustekinumab), and/or treatment.
  • Patients should be able and willing to comply with study visits and procedures as per protocol;
  • Patients should understand, sign and date the written voluntary form at the screening visit prior to any protocol-specific procedures being performed;
  • Patients should be affiliated to a social security regimen (for French sites only);
  • Females and males receiving the study treatment and their partners must agree to use a highly effective method during the study and for 3 months after end of study or early termination.

Exclusion criteria

Exclusion Criteria:

  • Patients with indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis or clinical/histologic findings suggestive of ulcerative colitis;
  • Patients with colonic dysplasia or neoplasia or adenomatous colonic polyp;
  • Patients with presence of fistulae;
  • Patients with current symptomatic diverticulitis or diverticulosis;
  • Patients with obstructive colonic stricture/stenosis, past medical history of colonic resection, a history of bowel surgery within 6 months before screening, or who are likely to require surgery for CD during the treatment period;
  • Patients with past medical history of short bowel syndrome;
  • Patients requiring parenteral nutrition;
  • Patients with past medical history of bowel surgery resulting in an existing or current stoma;
  • Patients with active infections at screening such as infected abdominal abscess, Clostridium difficile (stool antigen and toxin required), cytomegalovirus, tuberculous colitis and recent infectious hospitalization;
  • Acute, chronic or history of clinically relevant pulmonary, cardiovascular, hepatic, pancreatic or renal functional abnormality, encephalopathy, neuropathy or unstable central nervous system pathology such as seizure disorder, angina or cardiac arrhythmias, or any other clinically significant medical problems as determined by physical examination and/or laboratory screening tests and/or medical history;
  • Acute, chronic or history of immunodeficiency or disease;
  • History of excluding patients considered cure (5 years disease free survivors);
  • Active malignancy that may require chemotherapy or radiation therapy;
  • Serious illness requiring systemic treatment and/or hospitalization within 3 Weeks prior to baseline;
  • Pregnant or breast-feeding woman;
  • Illicit drug or alcohol abuse or dependence;
  • Use of any or non-registered product within 3 months or within 5 half-lives preceding baseline, whichever is longer;
  • Any condition, which in the opinion of the investigator, could compromise the patient's safety or adherence to the study protocol.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    ABX464 dose A

    Dose A QD

    Drug: ABX464

  • Experimental
    ABX464 Dose B

    Dose B QD

    Drug: ABX464

  • Placebo comparator
    Placebo

    Matching dose

    Drug: Placebo

Interventions

  • DrugABX464

    ABX464 is a new anti-inflammatory drug. In the treatment arm, patients will receive dose A or Dose B of ABX464 orally once daily for 52 weeks.

  • DrugPlacebo

    In the placebo group, patients will receive dose A or B ABX464-matching-placebo orally once daily for 52 weeks.

06

What researchers measure

Primary outcomes

  1. The co-primary objectives of the study are to determine the efficacy of ABX464 in inducing clinical remission and endoscopic improvement after 12 weeks of study treatment in patients with moderate to severe active CD who have inadequate response, loss of

    Percentage of patients in clinical remission at Week 12, defined as CDAI of ≤ 150

    Time frame: from baseline, at Week 12

  2. Co-primary objectives of the study are to determine the efficacy of ABX464 in inducing clinical remission and endoscopic improvement after 12 weeks of study treatment in patients with moderate to severe active CD who have inadequate response, loss of

    Percentage of patients with endoscopic improvement at Week 12, defined as a decrease from baseline of ≥ 50% in the global SES-CD (SES CD 50)

    Time frame: from baseline, at Week 12

Secondary outcomes

  1. To evaluate the safety of ABX464

    * Number and rate of all adverse events, causally related adverse events, all Serious Adverse Events (SAEs), and causally-related SAEs classified by severity * Incidence of treatment-emergent SAEs * Incidence of adverse events leading to investigational medicinal product discontinuation * The number of clinically-significant laboratory abnormalities

    Time frame: from baseline, at week 12

  2. To evaluate the effect of ABX464 as measured by Patient-Reported-Outcome-based remission (PRO) at Week 12

    Number and rates of patients with the following: PRO-based remission at Week 12, defined as abdominal pain ≤ 1 and liquid/soft Stool Frequence (SF) score of ≤ 3, averaged over the 7 days prior to visit

    Time frame: from baseline, at week 12

  3. To evaluate the effect of ABX464 on C reactive protein (CRP) and fecal calprotectin levels

    Change from Week 0 to Week 12 in CRP and fecal calprotectin levels

    Time frame: from baseline, at week 12

  4. To evaluate the effect of ABX464 on patients' quality of life

    The scores and changes from Week 0 to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ)

    Time frame: from baseline to week 12

  5. To evaluate the effect of ABX464 on micro RNA (miR) 124 expression in whole blood and in tissue

    Change from Week 0 to Week 12 in microRNA-124 levels in total blood (PAXgene®) and in tissue (RNA later)

    Time frame: from baseline to week 12

  6. To assess the pharmacokinetics of ABX464 and ABX464-N-Glu

    Serum concentration of ABX464 and its main metabolite ABX464-N-Glu levels

    Time frame: from baseline, at week 12

  7. To evaluate the effect of ABX464 as measured by endoscopic remission at Week 12

    Number and rates of patients with the following: Endoscopic remission at Week 12 defined as SES CD ≤ 4 with at least a 2 point reduction from baseline

    Time frame: from baseline, at week 12

  8. To evaluate the effect of ABX464 as measured by clinical response at Week 12

    Number and rates of patients with the following: Clinical response at Week 12, defined as a reduction from baseline in CDAI of ≥ 100 points

    Time frame: from baseline, at week 12

07

Study locations

1 site
  • University Hospitals Leuven - campus Gasthuisberg
    Leuven, 3000, Belgium
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2022; primary completion for Sep 2022, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2019
First posted
Apr 5, 2019
StartEst.
Sep 19, 2022
Primary completionEst.
Sep 19, 2022
CompletionEst.
Sep 19, 2022
Last update
Jul 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03905109
Lead sponsor
Abivax S.A.
Responsible party
Sponsor
First posted
Apr 5, 2019
Start date
Sep 19, 2022 (estimated)
Primary completion
Sep 19, 2022 (estimated)
Completion
Sep 19, 2022 (estimated)
Last update
Jul 31, 2024

Study contacts

Paul GINESTE, PharmD
study director · Abivax S.A.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABX464

Start the discussion